Elucidating the nociceptive role of CGRP in migraine headache
Brain · 03.08.2026 · 149 (8) · 2760-2773
DOI: 10.1093/brain/awag008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 08.01.2026. Verfasst von Agustin Melo-Carrillo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders, Nociception, Nociceptors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Calcitonin gene-related peptide (CGRP) is thought to be a key player in the pathogenesis of migraine, but there is a fundamental mystery in that the known neuronal actions of CGRP do not account for how it causes pain. We now report the first finding of CGRP-induced nociceptive neuronal activation using a novel method of intra-carotid infusion to achieve a more targeted delivery to cranial tissues. Single-unit recordings were performed in anaesthetized rats to measure CGRP effects on first- and second-order trigeminovascular neurons. CGRP was administered via intra-carotid infusion. Neuronal activation and sensitization were assessed by spontaneous firing rates and responses to mechanical stimulation of dural and facial receptive fields. Lidocaine was applied locally to the dura or trigeminal ganglion at varying time points to determine the peripheral contribution to CGRP-induced activity. Intra-carotid CGRP infusion (5 µg/kg/min, 20 min) activated 62% of Aδ-fibres and 56% of C-fibres, with significant increases in firing rates beginning within the first 30 min for Aδ-fibres and after 1 h for C-fibres. It also activated 75% of central trigeminovascular neurons, significantly increasing spontaneous firing and sensitizing dural and facial receptive fields. Similar effects were produced by CGRP injection into the trigeminal ganglion. These effects of CGRP were impeded by local anaesthetic blockade of the dura or trigeminal ganglion before but not 1 h after CGRP infusion. No significant sex differences were found in baseline firing or in the magnitude and timing of CGRP-induced responses across all neuron types. These findings provide the first evidence of peripheral nociceptive neuronal activation by CGRP, with a site of action in the meninges, and support a rationale for early, peripherally acting CGRP-targeted migraine treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.
- Department of Anesthesia, Harvard Medical School, Boston, MA 02115, USA.
ORCID-Profile: Rami Burstein
Förderung
- NINDS NIH HHS
- NIH
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Melo-Carrillo, A., Strassman, A. M., & Burstein, R. (2026). Elucidating the nociceptive role of CGRP in migraine headache. Brain, 149(8), 2760-2773. https://doi.org/10.1093/brain/awag008
Vancouver
Melo-Carrillo A, Strassman AM, Burstein R. Elucidating the nociceptive role of CGRP in migraine headache. Brain. 2026;149(8):2760-2773. doi:10.1093/brain/awag008
BibTeX
@article{MeloCarrillo2026,
author = {Melo-Carrillo, Agustin and Strassman, Andrew M and Burstein, Rami},
title = {Elucidating the nociceptive role of CGRP in migraine headache},
journal = {Brain},
year = {2026},
volume = {149},
number = {8},
pages = {2760--2773},
doi = {10.1093/brain/awag008}
}
EUVIMED